Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A proprietary preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells SJCAR19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.

**Synonyms:** - Autologous Anti-CD19 CAR-T Cells SJCAR19 - Autologous Anti-CD19 CART Cells SJCAR19 - Autologous CD19-specific CAR-T Cells SJCAR19 - SJCAR19